Satoshi Ebata

Publication Activity (10 Years)

Years Active: 2019-2022
Publications (10 Years): 11

Top Topics

Interstitial Lung Disease

Monoclonal Antibody

Clinical Evaluation

Top Venues

The Journal of dermatology

Arthritis & rheumatology (Hoboken, N.J.)

Journal of clinical medicine

Diagnostics (Basel, Switzerland)

This page only lists publications with an associated author ORCID identifier.

Publications

Ruriko Kawanabe, Ayumi Yoshizaki, Kazuki Mitsuru Matsuda, Hirohito Kotani, Teruyoshi Hisamoto, Yuta Norimatsu, Ai Kuzumi, Takemichi Fukasawa, Satoshi Ebata, Asako Yoshizaki-Ogawa, Shinichi Sato
Serum C-X-C Chemokine Ligand 1 Levels in Patients with Systemic Sclerosis: Relationship of Clinical and Laboratory Observations to Anti-CD20 Monoclonal Antibody Administration. Life (Basel, Switzerland) 12 (5) (2022)
Satoshi Ebata, Koji Oba, Kosuke Kashiwabara, Keiko Ueda, Yukari Uemura, Takeyuki Watadani, Takemichi Fukasawa, Shunsuke Miura, Asako Yoshizaki-Ogawa, Asano Yoshihide, Ayumi Yoshizaki, Shinichi Sato
Predictors of rituximab effect on modified Rodnan skin score in systemic sclerosis: a machine-learning analysis of the DesiReS trial. Rheumatology (Oxford, England) 61 (11) (2022)
Satoshi Ebata, Asako Yoshizaki-Ogawa, Shinichi Sato, Ayumi Yoshizaki
New Era in Systemic Sclerosis Treatment: Recently Approved Therapeutics. Journal of clinical medicine 11 (15) (2022)
Kazuki Mitsuru Matsuda, Ayumi Yoshizaki, Hirohito Kotani, Ai Kuzumi, Maiko Fukayama, Satoshi Ebata, Takemichi Fukasawa, Asako Yoshizaki-Ogawa, Shinichi Sato
Development of a prediction model of treatment response in patients with cutaneous arteritis: Insights from a cohort of 33 patients. The Journal of dermatology 48 (7) (2021)
Satoshi Ebata, Ayumi Yoshizaki, Takemichi Fukasawa, Asako Yoshizaki-Ogawa, Yoshihide Asano, Kosuke Kashiwabara, Koji Oba, Shinichi Sato
Increased Red Blood Cell Distribution Width in the First Year after Diagnosis Predicts Worsening of Systemic Sclerosis-Associated Interstitial Lung Disease at 5 Years: A Pilot Study. Diagnostics (Basel, Switzerland) 11 (12) (2021)
Satoshi Ebata, Ayumi Yoshizaki, Takemichi Fukasawa, Asako Yoshizaki-Ogawa, Yoshihide Asano, Kosuke Kashiwabara, Koji Oba, Shinichi Sato
Percentage of residual B cells after 2 weeks of rituximab treatment predicts the improvement of systemic sclerosis-associated interstitial lung disease. The Journal of dermatology (2021)
Hiroko Numajiri, Ai Kuzumi, Takemichi Fukasawa, Satoshi Ebata, Asako Yoshizaki-Ogawa, Yoshihide Asano, Yutaka Kazoe, Kazuma Mawatari, Takehiko Kitamori, Ayumi Yoshizaki, Shinichi Sato
B Cell Depletion Inhibits Fibrosis via Suppression of Profibrotic Macrophage Differentiation in a Mouse Model of Systemic Sclerosis. Arthritis & rheumatology (Hoboken, N.J.) 73 (11) (2021)
Satoshi Ebata, Ayumi Yoshizaki, Takemichi Fukasawa, Yoshihide Asano, Koji Oba, Shinichi Sato
Rapid decrease of serum surfactant protein-D levels predicts the reactivity of rituximab therapy in systemic sclerosis-associated interstitial lung disease. The Journal of dermatology 47 (7) (2020)
Maiko Fukayama, Ayumi Yoshizaki, Takemichi Fukasawa, Satoshi Ebata, Ai Kuzumi, Asako Yoshizaki-Ogawa, Yoshihide Asano, Koji Oba, Shinichi Sato
Interleukin (IL)-17F and IL-17E are related to fibrosis and vasculopathy in systemic sclerosis. The Journal of dermatology 47 (11) (2020)
Kazuki Mitsuru Matsuda, Ayumi Yoshizaki, Ai Kuzumi, Takemichi Fukasawa, Satoshi Ebata, Asako Yoshizaki-Ogawa, Shinichi Sato
Combined immunosuppressive therapy provides favorable prognosis and increased risk of cytomegalovirus reactivation in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis. The Journal of dermatology 47 (5) (2020)
Satoshi Ebata, Ayumi Yoshizaki, Takemichi Fukasawa, Shunsuke Miura, Takehiro Takahashi, Hayakazu Sumida, Yoshihide Asano, Shinichi Sato
Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease. The Journal of dermatology 46 (11) (2019)